Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

WANDA signs contract with HRS

4 Jan 2016 07:00

RNS Number : 6412K
NetScientific PLC
04 January 2016
 

 

NetScientific plc

 

 

WANDA signs contract with leading US home nursing and therapy service provider, HRS, to provide better care for patients with chronic conditions

 

London, UK - 4 January 2016 - NetScientific plc ("NetScientific" or the "Group", AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces that portfolio company, WANDA Inc. has signed a new contract with leading US high-tech home nursing and therapy services group, Health Resource Solutions ('HRS'). The deal enables HRS to use WANDA's chronic condition digital management platform to provide improved at home care to its patients.

 

WANDA's technology interacts with patients living with chronic conditions to intelligently detect vital sign and symptom information. Proven machine-learning techniques analyse each patient's information to enable them to better manage their health with easy-to-use digital tools. WANDA also provides clinicians with advanced decision support and collaboration tools, resulting in interventions to reduce expensive escalations and hospitalisations.

 

HRS is one of the most innovative and highly regarded home health agencies in the Chicago region and typically looks after over 1000 patients per month at any one time. HRS is certified by the Center for Medicare and Medicaid Services, the Community Health Accreditation Program and by the Illinois Department of Public Health to actively monitor and assist patients with chronic disease to give them a higher quality of life at home rather than being in a high acuity hospital setting. Wanda Health's solution will be used with some of HRS's congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD) patients.

 

The contract has been made directly with WANDA, and the first patients are expected to start using the platform and be billed on a monthly basis in the first quarter of 2016.

 

Francois Martelet, Group CEO of NetScientific, commented:

"WANDA is a leading portfolio company for NetScientific and our digital health franchise. Being selected by one of the leading high-tech home nursing and therapy services group in the US is an excellent endorsement of the potential WANDA's technology has to help improve people's lives by enabling them to stay at home and take more control to better manage their chronic conditions. "

 

- Ends -

 

Contact Details

NetScientific

François R. Martelet, M.D., CEO

Peter Thoms, CFO

Tel: +44 (0)20 3514 1800

 

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 

Instinctif Partners

Melanie Toyne-Sewell / Jayne Crook / Rosanna Forrest

Tel: +44 (0)20 7457 2020 Email: netscientific@instinctif.com

 

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment.

For more information, please visit the website at www.netscientific.net. 

 

About Health Resource Solutions

HRS is a privately owned home health agency servicing 11 counties in Illinois. HRS is licensed by the Illinois Department of Public Health, certified by the Center for Medicare and Medicaid Services (CMS) and accredited by the Community Health Accreditation Program, Inc. (CHAP). The purpose of HRS is to provide the best value in healthcare. We educate our clinical team to be the best practitioners. We combine our best practitioners with best practices to realize the best outcome. We also believe that utilizing technology to increase patient engagement combined with human touch will bring a better solution to home health care. More information about HRS can be found www.healthrs.net

 

About WANDA, Inc.

WANDA, Inc. supports efforts to improve the lives of those with chronic conditions by aiding decision making to help avoid costly adverse events through the use of proven machine intelligence and configurable medical rules. The company's advanced software accepts and immediately analyzes data from various remote devices and other data sources. WANDA is then able to recommend interventions and ultimately improve lives through better outcomes. Its real-time automated risk analysis gives care managers the prioritized visual guidance they need - relieving them of mundane data scanning while also lowering cost structures through more efficient use of care team resources and fewer hospital admissions among high-risk populations. More information about WANDA can be found at www.wandahealth.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTGGGDBDBGBGLS
Date   Source Headline
16th Sep 20242:31 pmRNSPDS: Updated Results, VERSATILE-002 Phase 2 Trial
13th Aug 20243:57 pmRNSPDS Biotech: Business Update and Q2 2024 Results
2nd Aug 202412:21 pmRNSReplacement RNS: PDS Biotech Aligns with FDA
2nd Aug 20247:00 amRNSPDS Biotech Aligns with FDA on Phase 3 Trial
30th Jul 20247:00 amRNSQ-Bot Fundraising
10th Jul 202410:48 amRNSResult of AGM
18th Jun 20247:00 amRNSNotice of AGM
14th Jun 20242:10 pmRNSTR-1
14th Jun 20247:00 amRNSDirector/PDMR Shareholding
13th Jun 20247:00 amRNSPreliminary Results for the year ended 31 Dec 2023
31st May 20247:01 amRNSNotice of Results and Investor Presentation
31st May 20247:00 amRNSDeepTech Recycling: Fundraising, Business Update
28th May 20247:00 amRNSInvestment in Wanda, related party transactions
15th May 20242:32 pmRNSPDS Biotech: Business Update and Q1 2024 Results
13th May 20247:00 amRNSMartlet Capital: mandate and acquisition
10th May 20249:12 amRNSPDS Biotech: Clinical trial meets study endpoints
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.